A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast CancerGang Chen, Leisha A. Emens, Richa Gupta et al.|Cancer Immunology Research|2014Cited by 92
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda Huff, Neeha Zaidi, Zirui Zhu et al.|Nature Communications|2026Cited by 15
Abstract CT264: Mutant KRAS peptide vaccine combined with ipilimumab/nivolumab in advanced mismatch repair proficient/microsatellite stable (MMRp/MSS) colorectal cancer: Preliminary analysis from a phase I studyHejia Wang, Neeha Zaidi, Amanda L. Huff et al.|Cancer Research|2025Cited by 3
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Wang, Neeha Zaidi, Amanda L. Huff et al.|Nature Communications|2026Cited by 1
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsSaurav D. Haldar, Neeha Zaidi, Amanda L. Huff et al.|Cancer Discovery|2026Cited by 1